{"id":835412,"date":"2025-04-09T07:57:58","date_gmt":"2025-04-09T11:57:58","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/darnatein-an-osr-company-broadens-intellectual-property-protection-for-innovative-osteoarthritis-treatment-technology\/"},"modified":"2025-04-09T07:57:58","modified_gmt":"2025-04-09T11:57:58","slug":"darnatein-an-osr-company-broadens-intellectual-property-protection-for-innovative-osteoarthritis-treatment-technology","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/darnatein-an-osr-company-broadens-intellectual-property-protection-for-innovative-osteoarthritis-treatment-technology\/","title":{"rendered":"Darnatein, an OSR Company, Broadens Intellectual Property Protection for Innovative Osteoarthritis Treatment Technology"},"content":{"rendered":"<div class=\"xn-newslines\">\n<p class=\"xn-distributor\">PR Newswire<\/p>\n<\/p><\/div>\n<div class=\"xn-content\">\n<p>\n        <span class=\"legendSpanClass\"><br \/>\n          <span class=\"xn-location\">SEOUL, South Korea<\/span><br \/>\n        <\/span>, <span class=\"legendSpanClass\"><span class=\"xn-chron\">April 9, 2025<\/span><\/span> \/PRNewswire\/ &#8212; Darnatein, a wholly-owned subsidiary of OSR Holdings, Inc. (NASDAQ: OSRH), today announces that it has successfully secured an additional international patent for its protein-based osteoarthritis treatment technology, marking a significant step in its expansion into the global market.<\/p>\n<div class=\"PRN_ImbeddedAssetReference\" id=\"DivAssetPlaceHolder1\">\n<p>\n          <a href=\"https:\/\/mma.prnewswire.com\/media\/2393302\/OSR_Holdings_logo_Logo.html\" target=\"_blank\" rel=\"nofollow\"><br \/>\n            <img decoding=\"async\" src=\"https:\/\/mma.prnewswire.com\/media\/2393302\/OSR_Holdings_logo_Logo.jpg\" title=\"OSR Holdings logo (PRNewsfoto\/OSR Holdings)\" alt=\"OSR Holdings logo (PRNewsfoto\/OSR Holdings)\" \/><br \/>\n          <\/a>\n        <\/p>\n<\/p><\/div>\n<p>\n        <b>Activin\/BMP7 Chimera Protein Technology Registered in <span class=\"xn-location\">China<\/span><\/b>\n      <\/p>\n<p>Darnatein has officially registered a patent with the China National Intellectual Property Administration (CNIPA) for the core technology behind its break-through disease-modifying osteoarthritis drug (DMOAD) lead drug candidate, DRT-101. Following the national registration of the patent in <span class=\"xn-location\">South Korea<\/span> in November last year, this marks the company&#8217;s first successful international patent registration as part of its efforts to secure global intellectual property rights through the PCT (Patent Cooperation Treaty) route in key regions such as the EU, <span class=\"xn-location\">the United States<\/span>, and <span class=\"xn-location\">China<\/span>.<\/p>\n<p>The technology basis is an AI-enhanced innovative protein structure generator designed to provide therapeutics that overcome the current limitations of standard of care treatment in osteoarthritis\u2014a condition for which only symptom management options currently exist. This technology represents a wholly new approach to protein design and is expected to address the underlying causes of disease. This treatment approach may significantly improve treatment outcomes not only for osteoarthritis but also for a wide range of other musculoskeletal disorders.<\/p>\n<p>In particular, the DRT-101 chimeric protein, which recombines the natural BMP7 and Activin proteins into a wholly novel structure, has already been shown to enhance both therapeutic efficacy and safety in vivo, in studies conducted between 2020 and 2024 at the <span class=\"xn-org\">University of California, San Diego<\/span>, School of Medicine.<\/p>\n<p>\n        <span class=\"xn-person\">Senyon Choe<\/span>, Darnatein Chief Executive Officer, stated, &#8220;The protein design technology now also patented in <span class=\"xn-location\">China<\/span> has been developed over years from a core platform strategy to the current technology with the potential to revolutionize the global OA treatment market. Securing intellectual property rights in <span class=\"xn-location\">China<\/span>, one of the largest markets in the world, is a crucial stepping-stone for our global expansion.&#8221;<\/p>\n<p>Constance H\u00f6fer, Chief Scientific Officer of OSR Holdings, stated, &#8220;Darnatein&#8217;s groundbreaking technology represents a wholly new, AI-enhanced approach to therapeutic protein design. The successful patent registration in <span class=\"xn-location\">China<\/span> underscores the novelty and relevance of this technology to the development of better treatment options for OA patients worldwide.&#8221;<\/p>\n<p>\n        <b>Global Technological Competitiveness and Licensing Potential<\/b>\n      <\/p>\n<p>The osteoarthritis treatment market continues to grow, due to globally aging populations. In 2023, the market size reached approximately <span class=\"xn-money\">USD 8.9 billion<\/span> and is projected to grow at an average annual rate of about 7%, reaching approximately <span class=\"xn-money\">USD 16.1 billion<\/span> by 2032. <span class=\"xn-location\">China<\/span> is experiencing rapid population aging and a surge in osteoarthritis cases, making it a highly promising market.<\/p>\n<p>Industry experts have remarked, &#8220;Darnatein&#8217;s Activin\/BMP7 chimera technology offers a superior profile to be developed into a potential DMOAD, or disease-modifying OA drug, compared to existing standard of care for osteoarthritis treatments,&#8221; adding, &#8220;Big Pharma is looking for novel treatments that can slow, stop, or even reverse the cartilage degeneration and joint damage that occurs with OA. On this backdrop, <span id=\"spanHghlt9716\">Darnatein&#8217;s<\/span> chimeric protein approach represents a paradigm shift away from only symptom relief (e.g. painkillers and anti-inflammatories) to treatment options targeting the underlying pathobiology of OA&#8221;<\/p>\n<p>Darnatein is currently completing preclinical studies with DRT-101, its degenerative OA treatment candidate, with the goal to initiate Phase 1 clinical trials later this year.<\/p>\n<p>\n        <b>About Darnatein<\/b>\n      <\/p>\n<p>Founded in 2012, Darnatein is a biotherapeutics company based in <span class=\"xn-location\">South Korea<\/span> developing a pipeline of innovative treatments for osteoarthritis and bone fusion, including DRT-101 as a ground breaking disease-modifying OA drug (DMOAD) candidate. Darnatein was established by Dr. <span class=\"xn-person\">Senyon Choe<\/span>, one of the co-founders of the structural protein laboratory of the prestigious Salk Institute for Biological Studies in <span class=\"xn-location\">La Jolla, CA<\/span>, and a faculty member of UC San Diego since 1993. Darnatein operates as a wholly owned subsidiary of OSR Holdings, Inc. following its acquisition in <span id=\"spanHghlt5e44\">2023.<\/span>\u00a0<\/p>\n<p>\n        <b>About OSR Holdings, Inc.<\/b>\n      <\/p>\n<p>OSR Holdings, Inc. is a global healthcare company dedicated to advancing biomedical innovation. Through its subsidiaries, OSR is engaged in oncology immunotherapies, degenerative disease biologics, and medical device distribution. OSR&#8217;s vision is to acquire and operate a portfolio of innovative healthcare companies, improving patient care through cutting-edge research and development. For more information, visit <a href=\"http:\/\/www.osr-holdings.com\/\" target=\"_blank\" rel=\"nofollow\">www.OSR-Holdings.com<\/a>.<\/p>\n<p>\n        <b>Contact<\/b>\n      <\/p>\n<p>\n        <a href=\"mailto:ir@osr-holdings.com\" target=\"_blank\" rel=\"nofollow\">ir@osr-holdings.com<\/a>\n      <\/p>\n<p>\u00a0<\/p>\n<p id=\"PURL\">\n        <img loading=\"lazy\" decoding=\"async\" title=\"Cision\" width=\"12\" height=\"12\" alt=\"Cision\" src=\"https:\/\/c212.net\/c\/img\/favicon.png?sn=CN61037&amp;sd=2025-04-09\" \/> View original content to download multimedia:<a id=\"PRNURL\" rel=\"nofollow\" href=\"https:\/\/www.prnewswire.com\/news-releases\/darnatein-an-osr-company-broadens-intellectual-property-protection-for-innovative-osteoarthritis-treatment-technology-302424483.html\" target=\"_blank\">https:\/\/www.prnewswire.com\/news-releases\/darnatein-an-osr-company-broadens-intellectual-property-protection-for-innovative-osteoarthritis-treatment-technology-302424483.html<\/a><\/p>\n<p>SOURCE  OSR Holdings Inc.<\/p>\n<\/p><\/div>\n<p>    <img decoding=\"async\" alt=\"\" src=\"https:\/\/rt.prnewswire.com\/rt.gif?NewsItemId=CN61037&amp;Transmission_Id=202504090754PR_NEWS_USPR_____CN61037&amp;DateId=20250409\" style=\"border:0px;width:1px;height:1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>PR Newswire SEOUL, South Korea , April 9, 2025 \/PRNewswire\/ &#8212; Darnatein, a wholly-owned subsidiary of OSR Holdings, Inc. (NASDAQ: OSRH), today announces that it has successfully secured an additional international patent for its protein-based osteoarthritis treatment technology, marking a significant step in its expansion into the global market. Activin\/BMP7 Chimera Protein Technology Registered in China Darnatein has officially registered a patent with the China National Intellectual Property Administration (CNIPA) for the core technology behind its break-through disease-modifying osteoarthritis drug (DMOAD) lead drug candidate, DRT-101. Following the national registration of the patent in South Korea in November last year, this marks the company&#8217;s first successful international patent registration as part of its efforts to secure global intellectual property rights through &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/darnatein-an-osr-company-broadens-intellectual-property-protection-for-innovative-osteoarthritis-treatment-technology\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Darnatein, an OSR Company, Broadens Intellectual Property Protection for Innovative Osteoarthritis Treatment Technology&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-835412","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Darnatein, an OSR Company, Broadens Intellectual Property Protection for Innovative Osteoarthritis Treatment Technology - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/darnatein-an-osr-company-broadens-intellectual-property-protection-for-innovative-osteoarthritis-treatment-technology\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Darnatein, an OSR Company, Broadens Intellectual Property Protection for Innovative Osteoarthritis Treatment Technology - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"PR Newswire SEOUL, South Korea , April 9, 2025 \/PRNewswire\/ &#8212; Darnatein, a wholly-owned subsidiary of OSR Holdings, Inc. (NASDAQ: OSRH), today announces that it has successfully secured an additional international patent for its protein-based osteoarthritis treatment technology, marking a significant step in its expansion into the global market. Activin\/BMP7 Chimera Protein Technology Registered in China Darnatein has officially registered a patent with the China National Intellectual Property Administration (CNIPA) for the core technology behind its break-through disease-modifying osteoarthritis drug (DMOAD) lead drug candidate, DRT-101. Following the national registration of the patent in South Korea in November last year, this marks the company&#8217;s first successful international patent registration as part of its efforts to secure global intellectual property rights through &hellip; Continue reading &quot;Darnatein, an OSR Company, Broadens Intellectual Property Protection for Innovative Osteoarthritis Treatment Technology&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/darnatein-an-osr-company-broadens-intellectual-property-protection-for-innovative-osteoarthritis-treatment-technology\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-04-09T11:57:58+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mma.prnewswire.com\/media\/2393302\/OSR_Holdings_logo_Logo.jpg\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/darnatein-an-osr-company-broadens-intellectual-property-protection-for-innovative-osteoarthritis-treatment-technology\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/darnatein-an-osr-company-broadens-intellectual-property-protection-for-innovative-osteoarthritis-treatment-technology\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Darnatein, an OSR Company, Broadens Intellectual Property Protection for Innovative Osteoarthritis Treatment Technology\",\"datePublished\":\"2025-04-09T11:57:58+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/darnatein-an-osr-company-broadens-intellectual-property-protection-for-innovative-osteoarthritis-treatment-technology\\\/\"},\"wordCount\":726,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/darnatein-an-osr-company-broadens-intellectual-property-protection-for-innovative-osteoarthritis-treatment-technology\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/2393302\\\/OSR_Holdings_logo_Logo.jpg\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/darnatein-an-osr-company-broadens-intellectual-property-protection-for-innovative-osteoarthritis-treatment-technology\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/darnatein-an-osr-company-broadens-intellectual-property-protection-for-innovative-osteoarthritis-treatment-technology\\\/\",\"name\":\"Darnatein, an OSR Company, Broadens Intellectual Property Protection for Innovative Osteoarthritis Treatment Technology - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/darnatein-an-osr-company-broadens-intellectual-property-protection-for-innovative-osteoarthritis-treatment-technology\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/darnatein-an-osr-company-broadens-intellectual-property-protection-for-innovative-osteoarthritis-treatment-technology\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/2393302\\\/OSR_Holdings_logo_Logo.jpg\",\"datePublished\":\"2025-04-09T11:57:58+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/darnatein-an-osr-company-broadens-intellectual-property-protection-for-innovative-osteoarthritis-treatment-technology\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/darnatein-an-osr-company-broadens-intellectual-property-protection-for-innovative-osteoarthritis-treatment-technology\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/darnatein-an-osr-company-broadens-intellectual-property-protection-for-innovative-osteoarthritis-treatment-technology\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/2393302\\\/OSR_Holdings_logo_Logo.jpg\",\"contentUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/2393302\\\/OSR_Holdings_logo_Logo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/darnatein-an-osr-company-broadens-intellectual-property-protection-for-innovative-osteoarthritis-treatment-technology\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Darnatein, an OSR Company, Broadens Intellectual Property Protection for Innovative Osteoarthritis Treatment Technology\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Darnatein, an OSR Company, Broadens Intellectual Property Protection for Innovative Osteoarthritis Treatment Technology - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/darnatein-an-osr-company-broadens-intellectual-property-protection-for-innovative-osteoarthritis-treatment-technology\/","og_locale":"en_US","og_type":"article","og_title":"Darnatein, an OSR Company, Broadens Intellectual Property Protection for Innovative Osteoarthritis Treatment Technology - Market Newsdesk","og_description":"PR Newswire SEOUL, South Korea , April 9, 2025 \/PRNewswire\/ &#8212; Darnatein, a wholly-owned subsidiary of OSR Holdings, Inc. (NASDAQ: OSRH), today announces that it has successfully secured an additional international patent for its protein-based osteoarthritis treatment technology, marking a significant step in its expansion into the global market. Activin\/BMP7 Chimera Protein Technology Registered in China Darnatein has officially registered a patent with the China National Intellectual Property Administration (CNIPA) for the core technology behind its break-through disease-modifying osteoarthritis drug (DMOAD) lead drug candidate, DRT-101. Following the national registration of the patent in South Korea in November last year, this marks the company&#8217;s first successful international patent registration as part of its efforts to secure global intellectual property rights through &hellip; Continue reading \"Darnatein, an OSR Company, Broadens Intellectual Property Protection for Innovative Osteoarthritis Treatment Technology\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/darnatein-an-osr-company-broadens-intellectual-property-protection-for-innovative-osteoarthritis-treatment-technology\/","og_site_name":"Market Newsdesk","article_published_time":"2025-04-09T11:57:58+00:00","og_image":[{"url":"https:\/\/mma.prnewswire.com\/media\/2393302\/OSR_Holdings_logo_Logo.jpg","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/darnatein-an-osr-company-broadens-intellectual-property-protection-for-innovative-osteoarthritis-treatment-technology\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/darnatein-an-osr-company-broadens-intellectual-property-protection-for-innovative-osteoarthritis-treatment-technology\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Darnatein, an OSR Company, Broadens Intellectual Property Protection for Innovative Osteoarthritis Treatment Technology","datePublished":"2025-04-09T11:57:58+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/darnatein-an-osr-company-broadens-intellectual-property-protection-for-innovative-osteoarthritis-treatment-technology\/"},"wordCount":726,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/darnatein-an-osr-company-broadens-intellectual-property-protection-for-innovative-osteoarthritis-treatment-technology\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/2393302\/OSR_Holdings_logo_Logo.jpg","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/darnatein-an-osr-company-broadens-intellectual-property-protection-for-innovative-osteoarthritis-treatment-technology\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/darnatein-an-osr-company-broadens-intellectual-property-protection-for-innovative-osteoarthritis-treatment-technology\/","name":"Darnatein, an OSR Company, Broadens Intellectual Property Protection for Innovative Osteoarthritis Treatment Technology - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/darnatein-an-osr-company-broadens-intellectual-property-protection-for-innovative-osteoarthritis-treatment-technology\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/darnatein-an-osr-company-broadens-intellectual-property-protection-for-innovative-osteoarthritis-treatment-technology\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/2393302\/OSR_Holdings_logo_Logo.jpg","datePublished":"2025-04-09T11:57:58+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/darnatein-an-osr-company-broadens-intellectual-property-protection-for-innovative-osteoarthritis-treatment-technology\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/darnatein-an-osr-company-broadens-intellectual-property-protection-for-innovative-osteoarthritis-treatment-technology\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/darnatein-an-osr-company-broadens-intellectual-property-protection-for-innovative-osteoarthritis-treatment-technology\/#primaryimage","url":"https:\/\/mma.prnewswire.com\/media\/2393302\/OSR_Holdings_logo_Logo.jpg","contentUrl":"https:\/\/mma.prnewswire.com\/media\/2393302\/OSR_Holdings_logo_Logo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/darnatein-an-osr-company-broadens-intellectual-property-protection-for-innovative-osteoarthritis-treatment-technology\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Darnatein, an OSR Company, Broadens Intellectual Property Protection for Innovative Osteoarthritis Treatment Technology"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/835412","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=835412"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/835412\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=835412"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=835412"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=835412"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}